STOCK TITAN

Exicure, Inc. - $XCUR STOCK NEWS

Welcome to our dedicated page for Exicure news (Ticker: $XCUR), a resource for investors and traders seeking the latest updates and insights on Exicure stock.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Exicure's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Exicure's position in the market.

Rhea-AI Summary
Exicure, Inc. received a Nasdaq Delinquency Notice for failing to timely file its Annual Report on Form 10-K, leading to non-compliance with Nasdaq Listing Rule 5250(c)(1). The company must submit an updated plan to regain compliance by May 20, 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary
Exicure, Inc. (NASDAQ: XCUR) has entered into a patent license agreement with Bluejay Therapeutics, Inc. to develop cavrotolimod for potential treatment for hepatitis. Bluejay will receive an exclusive license to all of Exicure's relevant patents and will pay an initial small, one-time payment to Exicure. Exicure will also receive modest royalties on future net sales of the licensed technology. The partnership aims to expand the use case of cavrotolimod beyond Exicure's historical focus on oncology.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
27.5%
Tags
none
-
Rhea-AI Summary
Exicure, Inc. (Nasdaq: XCUR) received a notice of non-compliance from Nasdaq due to the delayed filing of its Quarterly Report on Form 10-Q. The company has 60 days to submit a plan to regain compliance and can be granted up to 180 days to do so. Exicure is working diligently to complete the form and intends to file it as soon as possible.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6%
Tags
none
Rhea-AI Summary
Exicure, Inc. appoints new CEO and CFO, and new directors to the Board
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.84%
Tags
management
-
Rhea-AI Summary
Exicure, Inc. (XCUR) announced a significant reduction in force, suspension of preclinical activities, and halting of all research and development. The company is exploring strategic alternatives to maximize stockholder value. Recent highlights include entering into subscription agreements with Cyworld Z Co., Ltd. and second quarter 2023 financial results.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
Rhea-AI Summary
Exicure announces ongoing efforts to explore strategic alternatives to maximize stockholder value, with the appointment of Jung Sang (Michael) Kim as CEO and CFO. The Board fully supports Mr. Kim's strategic vision and efforts to identify potential transaction alternatives, including asset sales and partnerships with unrelated industries. No assurance of any transaction or alternative.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.95%
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.96%
Tags
management
Exicure, Inc.

Nasdaq:XCUR

XCUR Rankings

XCUR Stock Data

4.16M
7.81M
45.04%
9.8%
2.09%
Research and Development in Biotechnology
Professional, Scientific, and Technical Services
Link
United States of America
CHICAGO

About XCUR

exicure, formerly aurasense therapeutics, is developing a new class of immunomodulatory and gene silencing drugs against validated targets. our 3-dimensional, spherical nucleic acid (sna™) architecture unlocks the potential of nucleic acid therapeutics in multiple organs. our lead programs address diseases from inflammatory disorders to oncology. sna constructs overcome one of the most difficult obstacles to nucleic acid therapeutics: safe and effective delivery into cells and tissues. sna constructs exhibit unparalleled transfection efficiency into numerous cell and tissue types including the skin without carriers or transfection agents. moreover, snas can be used as potent immunotherapeutic agents for the treatment of cancer or infectious disease.